Gilead Sciences, Inc. and Kymera Therapeutics, Inc. have announced an exclusive option and license agreement aimed at advancing a novel class of cancer treatments: molecular glue degraders (MGDs) targeting cyclin-dependent kinase 2 (CDK2). The collaboration seeks to accelerate development of a promising oral therapy with potential applications in breast cancer and other solid tumors.
Unlike traditional CDK2 inhibitors that merely block the activity of the protein, Kymera’s MGDs are designed to eliminate CDK2 entirely from cancer cells. This approach could offer more precise and safer treatment by reducing the off-target effects typically seen with conventional inhibitors, which often affect other, similar proteins.
“MGDs are opening exciting new possibilities in cancer research by eliminating disease-driving proteins rather than just blocking them,” said Dr. Flavius Martin, Executive Vice President of Research at Gilead Sciences. “We’re thrilled to partner with Kymera to bring this novel oral program closer to patients with cancers that urgently need better treatment options.”
The agreement marks the first disclosed molecular glue program from Kymera, a leader in targeted protein degradation. According to Dr. Nello Mainolfi, Kymera’s Founder and CEO, the CDK2-focused MGDs have shown a strong preclinical profile, including high selectivity and potency. “This collaboration reflects our shared commitment to pushing the boundaries of drug discovery,” Mainolfi said.
The partnership underscores both companies’ strategic focus on innovative cancer therapeutics, especially in areas where current treatments fall short. Further financial terms of the agreement were not disclosed.